Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
10.42
+0.16 (1.56%)
Jan 21, 2025, 4:00 PM EST - Market closed
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CGEM stock have an average target of 31.67, with a low estimate of 26 and a high estimate of 40. The average target predicts an increase of 203.93% from the current stock price of 10.42.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 24, 2024.
Analyst Ratings
The average analyst rating for CGEM stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +187.91% | Oct 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +168.71% | Oct 16, 2024 |
| Wedbush | Wedbush | Buy Reiterates $36 | Buy | Reiterates | $36 | +245.49% | Sep 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +168.71% | Sep 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +168.71% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
8.56M
EPS This Year
-3.17
from -3.69
EPS Next Year
-3.23
from -3.17
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 47.3M | 76.3M | |||
| Avg | n/a | 8.6M | 28.4M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 792.1% | |||
| Avg | - | - | 231.4% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.18 | -2.68 | -2.60 | |||
| Avg | -3.17 | -3.23 | -3.21 | |||
| Low | -3.35 | -4.07 | -4.66 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.